Related references
Note: Only part of the references are listed.Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
Mohammed Al-Hamadani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The biology and management of systemic anaplastic large cell lymphoma
Greg Hapgood et al.
BLOOD (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Madeleine Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
JM Foran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
